Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Dec 29 2025

0mins

MNPR-6.38%

Should l Buy MNPR?

Source: NASDAQ.COM

Insider Purchase: Monopar Therapeutics CFO Quan Anh Vu purchased 1,500 shares of MNPR at $69.95 each on Friday, totaling an investment of $104,925, indicating confidence in the company's future prospects.
Market Reaction: Despite Vu's purchase signaling optimism about the company's outlook, MNPR's stock fell approximately 1.1% on Monday, reflecting market caution regarding the company's current situation.
Purchase Frequency: This marks Vu's first stock purchase in the past 12 months, potentially indicating a reassessment of the company's value or expectations for future performance.
Investor Confidence: Insider buying is generally viewed as a positive signal for the company's future, which may bolster confidence among other investors, even though the stock's short-term performance remains weak.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MNPR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MNPR

Wall Street analysts forecast MNPR stock price to rise

11 Analyst Rating

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 59.240

Low

95.00

Averages

112.91

High

130.00

Current: 59.240

Low

95.00

Averages

112.91

High

130.00

Morgan Stanley

Maxwell Skor

Overweight

initiated

$115

2026-01-09

Reason

Morgan Stanley

Maxwell Skor

Price Target

$115

AI Analysis

2026-01-09

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics with an Overweight rating and $115 price target. The firm says ALXN1840 demonstrated "meaningful" copper mobilization and neurological benefit in a Phase 3 study as a "differentiated therapy" for Wilson's disease with a once-daily profile. The analyst sees an "encouraging set-up" for the shares.

Raymond James

Christopher Raymond

Strong Buy -> Outperform

downgrade

$142 -> $123

2025-11-14

Reason

Raymond James

Christopher Raymond

Price Target

$142 -> $123

2025-11-14

downgrade

Strong Buy -> Outperform

Reason

Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm's key opinion leader feedback indicates a "heavier commercial" lift than first imagined for Monopar in Wilson disease. A " higher risk premium to our estimates is warranted here," the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MNPR

Unlock Now

About MNPR

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings

Jan 09 2026CNBC

Price Target Adjustment: Goldman Sachs has cut its price target for Netflix from $130 to $112, reflecting a cautious outlook ahead of the upcoming earnings report, which is expected to show solid performance by the end of 2025 as management executes its core strategic focus.
Content Strategy: Goldman emphasizes that Netflix will continue to rely on original and returning original content to drive user engagement and growth, a strategy that may impact user retention and market share in the competitive streaming landscape.
Market Expectations: While Goldman maintains a neutral rating on Netflix, the market's reaction to the forthcoming earnings report could lead to stock price volatility, particularly given the uncertainties in the macroeconomic environment.
Competitive Pressure: Netflix faces competitive pressures from other streaming platforms, especially regarding content richness and user experience, which could affect its growth potential moving forward.

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

Dec 31 2025Benzinga

Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.